US2007020265A1PendingUtilityA1
Immunotherapy of autoimmune disorders using antibodies which target b-cells
Est. expiryJun 9, 2019(expired)· nominal 20-yr term from priority
A61P 37/06A61P 9/00A61P 31/12A61P 5/14A61P 7/06A61P 3/10A61P 37/02A61P 37/00A61P 35/00A61P 7/04A61P 25/28A61P 25/00A61P 29/00A61K 45/06A61K 2039/505C07K 2317/24A61P 11/00A61K 38/00A61P 19/02C07K 16/2803A61P 1/16C07K 16/2896A61P 1/04C07K 16/2887C07K 16/28A61P 21/04A61K 47/6849A61P 21/00A61P 13/12A61K 39/3955A61P 19/00A61P 19/08A61K 2039/507A61K 47/6813A61K 39/395
64
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Antibodies that bind with a B-cell antigen provide an effective means to treat autoinmune disorders. Antibodies and fragments, which may be conjugated or naked, are used alone or in multimodal therapies. The antibodies may be bispecific antibodies which may be produced recombinantly as fusion proteins, or as hybrid, polyspecific antibodies.
Claims
exact text as granted — not AI-modified1 . A method of treating an autoimmune disease in a subject comprising administering an anti-CD20 antibody and an anti-TNFα antagonist or anti-IL-1 antagonist.
2 . A method according to claim 1 , wherein said anti-TNFα or anti-IL-1 antagonist is administered before said anti-CD20 antibody.
3 . A method according to claim 1 , wherein said anti-TNFα or anti-IL-1 antagonist is administered after said anti-CD20 antibody.
4 . A method according to claim 1 , wherein said anti-TNFα or anti-IL-1 antagonist is administered concurrently with said anti-CD20 antibody.
5 . A method according to claim 1 , comprising administering an anti-CD20 antibody and an anti-TNFα antagonist.
6 . A method according to claim 5 , wherein said anti-TNFα antagonist is administered before said anti-CD20 antibody.
7 . A method according to claim 5 , wherein said anti-TNFα antagonist is administered after said anti-CD20 antibody.
8 . A method according to claim 5 , wherein said anti-TNFα antagonist is administered concurrently with said anti-CD20 antibody.
9 . A method according to claim 1 , comprising administering an anti-CD20 antibody and an anti-IL-1 antagonist.
10 . A method according to claim 5 , wherein said anti-IL-1 antagonist is administered before said anti-CD20 antibody.
11 . A method according to claim 5 , wherein said anti-IL-1 antagonist is administered after said anti-CD20 antibody.
12 . A method according to claim 5 , wherein said anti-IL-1 antagonist is administered concurrently with said anti-CD20 antibody.
13 . A method according to claim 1 , wherein said anti-TNFα antagonist is an anti-TNFα antibody and said anti-IL-1 antagonist is an anti-IL-1 antagonist is an anti-IL-1 antibody.
14 . A method according to claim 1 , comprising administering an anti-CD20 antibody and an anti-TNFα antibody.
15 . A method according to claim 1 , comprising administering an anti-CD20 antibody and an anti-IL-1 antibody.
16 . A method according to claim 1 , wherein said autoimmune disease is rheumatoid arthritis.
17 . A method according to claim 14 , wherein said autoimmune disease is rheumatoid arthritis.
18 . A method according to claim 15 , wherein said autoimmune disease is rheumatoid arthritis.Join the waitlist — get patent alerts
Track US2007020265A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.